More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.24B
EPS
2.19
P/E ratio
15.6
Price to sales
1.55
Dividend yield
--
Beta
0.930502
Previous close
$29.37
Today's open
$29.75
Day's range
$29.11 - $30.10
52 week range
$16.65 - $31
show more
CEO
Jack Yongfeng Zhang
Employees
1976
Headquarters
Rancho Cucamonga, CA
Exchange
Nasdaq Global Select
Shares outstanding
42652154
Issue type
Common Stock
Healthcare
Pharmaceuticals
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London
RANCHO CUCAMONGA, Calif., Nov. 11, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be participating in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference in London on Wednesday, November 18th, 2026, at 12:00 pm GMT.
PRNewsWire • Nov 11, 2026

Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2026 Earnings Call Transcript
Amphastar Pharmaceuticals, Inc. ( AMPH ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Dan Dischner - Senior Vice President of Human Resources & Corporate Communication William Peters - CFO, Executive VP of Finance, Treasurer & Director Conference Call Participants Ekaterina Knyazkova - JPMorgan Chase & Co, Research Division Naoki Martin - Piper Sandler & Co., Research Division Yuchen Ding - Jefferies LLC, Research Division Serge Belanger - Needham & Company, LLC, Research Division Jason Gerberry - BofA Securities, Research Division Glen Santangelo - Barclays Bank PLC, Research Division Presentation Operator Greetings, and welcome to the Amphastar Pharmaceuticals Inc. Third Quarter Earnings Call. [Operator Instructions] Please note that certain statements made during this call regarding matters that are not historical facts, including, but not limited to, management's outlook or predictions for future periods are forward-looking statements.
Seeking Alpha • Nov 6, 2026

Amphastar Pharmaceuticals Q3 Earnings Call Highlights
Amphastar Pharmaceuticals NASDAQ: AMPH reported record third-quarter revenue of $207.6 million, up 8% from a year earlier, as sales of BAQSIMI and Primatene MIST and contributions from newer products offset manufacturing disruptions and lower pricing on some established medicines.
MarketBeat • Nov 6, 2026

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026
Net revenues of $207.6 million for the three months ended September 30, 2026 GAAP net income of $37.8 million, or $0.87 per share, for the third quarter Adjusted non-GAAP net income of $49.3 million, or $1.14 per share, for the third quarter Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, Calif.
PRNewsWire • Nov 5, 2026

Amphastar Pharmaceuticals (AMPH) Tops Q3 Earnings and Revenue Estimates
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.93 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Amphastar (AMPH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks Investment Research • Nov 6, 2026

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026
RANCHO CUCAMONGA, Calif., October 29, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the Company will release results for its third quarter of 2026 ended September 30, 2026, after the market closes on Thursday, November 5, 2026, and will hold a conference call to discuss its financial results at 2:00 p.m.
PRNewsWire • Oct 29, 2026

Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Oct 29, 2026

Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Investment Research • Oct 6, 2026

Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference
RANCHO CUCAMONGA, Calif., Sept. 1, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8th, 2026, at 4:30 pm ET.
PRNewsWire • Sep 1, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Amphastar Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.